Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Factors associated with prior engagement in high-risk sexual behaviours among adolescents (10-19 years) in a pastoralist post-conflict community, Karamoja sub-region, North eastern Uganda.

Ssebunya RN, Matovu JKB, Makumbi FE, Kisitu GP, Maganda A, Kekitiinwa A.

BMC Public Health. 2019 Jul 31;19(1):1027. doi: 10.1186/s12889-019-7352-6.

2.

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe.

Prendergast AJ, Berejena C, Pimundu G, Shonhai A, Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Cook AD, Spyer MJ, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Klein N, Walker AS.

AIDS. 2019 Jul 15;33(9):1485-1490. doi: 10.1097/QAD.0000000000002231.

PMID:
31008797
3.

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.

Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L, Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A, Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein N, Edens TJ, Walker AS, Manges AR, Prendergast AJ.

Sci Transl Med. 2019 Apr 3;11(486). pii: eaav0537. doi: 10.1126/scitranslmed.aav0537.

4.

Saving Mothers, Giving Life: It Takes a System to Save a Mother (Republication).

Conlon CM, Serbanescu F, Marum L, Healey J, LaBrecque J, Hobson R, Levitt M, Kekitiinwa A, Picho B, Soud F, Spigel L, Steffen M, Velasco J, Cohen R, Weiss W.

Glob Health Sci Pract. 2019 Mar 29;7(1):20-40. doi: 10.9745/GHSP-D-19-00092. Print 2019 Mar 22.

5.

Decreased Prevalence of Rheumatic Heart Disease Confirmed Among HIV-positive Youth.

Hovis IW, Namuyonga J, Kisitu GP, Ndagire E, Okello E, Longenecker CT, Sanyahumbi A, Sable CA, Penny DJ, Lwabi P, Kekitiinwa AR, Beaton A.

Pediatr Infect Dis J. 2019 Apr;38(4):406-409. doi: 10.1097/INF.0000000000002161.

PMID:
30882733
6.

Sustainability and Scale of the Saving Mothers, Giving Life Approach in Uganda and Zambia.

Healey J, Conlon CM, Malama K, Hobson R, Kaharuza F, Kekitiinwa A, Levitt M, Zulu DW, Marum L.

Glob Health Sci Pract. 2019 Mar 13;7(Suppl 1):S188-S206. doi: 10.9745/GHSP-D-18-00265. Print 2019 Mar 11.

7.

Addressing the Third Delay in Saving Mothers, Giving Life Districts in Uganda and Zambia: Ensuring Adequate and Appropriate Facility-Based Maternal and Perinatal Health Care.

Morof D, Serbanescu F, Goodwin MM, Hamer DH, Asiimwe AR, Hamomba L, Musumali M, Binzen S, Kekitiinwa A, Picho B, Kaharuza F, Namukanja PM, Murokora D, Kamara V, Dynes M, Blanton C, Nalutaaya A, Luwaga F, Schmitz MM, LaBrecque J, Conlon CM, McCarthy B, Kroelinger C, Clark T.

Glob Health Sci Pract. 2019 Mar 13;7(Suppl 1):S85-S103. doi: 10.9745/GHSP-D-18-00272. Print 2019 Mar 11.

8.

Impact of the Saving Mothers, Giving Life Approach on Decreasing Maternal and Perinatal Deaths in Uganda and Zambia.

Serbanescu F, Clark TA, Goodwin MM, Nelson LJ, Boyd MA, Kekitiinwa AR, Kaharuza F, Picho B, Morof D, Blanton C, Mumba M, Komakech P, Carlosama F, Schmitz MM, Conlon CM.

Glob Health Sci Pract. 2019 Mar 13;7(Suppl 1):S27-S47. doi: 10.9745/GHSP-D-18-00428. Print 2019 Mar 11.

9.

Saving Mothers, Giving Life: It Takes a System to Save a Mother.

Conlon CM, Serbanescu F, Marum L, Healey J, LaBrecque J, Hobson R, Levitt M, Kekitiinwa A, Picho B, Soud F, Spigel L, Steffen M, Velasco J, Cohen R, Weiss W.

Glob Health Sci Pract. 2019 Mar 13;7(Suppl 1):S6-S26. doi: 10.9745/GHSP-D-18-00427. Print 2019 Mar 11.

10.

The Collaborative African Genomics Network (CAfGEN): Applying Genomic technologies to probe host factors important to the progression of HIV and HIV-tuberculosis infection in sub-Saharan Africa.

Mboowa G, Mwesigwa S, Katagirya E, Retshabile G, Mlotshwa BC, Williams L, Kekitiinwa A, Kateete D, Wampande E, Wayengera M, Kintu BN, Kisitu GP, Kyobe S, Brown CW, Hanchard NA, Mardon G, Joloba M, Anabwani G, Pettitt E, Tsimako-Johnstone M, Kasvosve I, Maplanka K, Mpoloka SW, Hlatshwayo M, Matshaba M.

AAS Open Res. 2018 Apr 18;1:3. doi: 10.12688/aasopenres.12832.1.

11.

Factors Influencing the Risk of Becoming Sexually Active Among HIV Infected Adolescents in Kampala and Kisumu, East Africa.

Bakeera-Kitaka S, Smekens T, Jespers V, Wobudeya E, Loos J, Colebunders R, Adipo D, Kekitiinwa A, Musoke P, Buve A, Nöstlinger C.

AIDS Behav. 2019 Jun;23(6):1375-1386. doi: 10.1007/s10461-018-2323-y.

PMID:
30406334
12.

Decentralisation of child tuberculosis services increases case finding and uptake of preventive therapy in Uganda.

Zawedde-Muyanja S, Nakanwagi A, Dongo JP, Sekadde MP, Nyinoburyo R, Ssentongo G, Detjen AK, Mugabe F, Nakawesi J, Karamagi Y, Amuge P, Kekitiinwa A, Graham SM.

Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1314-1321. doi: 10.5588/ijtld.18.0025.

PMID:
30355411
13.

Retention outcomes and drivers of loss among HIV-exposed and infected infants in Uganda: a retrospective cohort study.

Kiyaga C, Narayan V, McConnell I, Elyanu P, Kisaakye LN, Kekitiinwa A, Price M, Grosz J.

BMC Infect Dis. 2018 Aug 22;18(1):416. doi: 10.1186/s12879-018-3275-6.

14.

Retention of HIV-Positive Adolescents in Care: A Quality Improvement Intervention in Mid-Western Uganda.

Izudi J, Mugenyi J, Mugabekazi M, Muwanika B, Tumukunde Spector V, Katawera A, Kekitiinwa A.

Biomed Res Int. 2018 May 6;2018:1524016. doi: 10.1155/2018/1524016. eCollection 2018.

15.

Prevalence and correlates of HIV testing among adolescents 10-19 years in a post-conflict pastoralist community of Karamoja region, Uganda.

Ssebunya RN, Wanyenze RK, Namale L, Lukolyo H, Kisitu GP, Nahirya-Ntege P, Kekitiinwa A.

BMC Public Health. 2018 May 10;18(1):612. doi: 10.1186/s12889-018-5544-0.

16.

The relationship between leadership style and health worker motivation, job satisfaction and teamwork in Uganda.

Musinguzi C, Namale L, Rutebemberwa E, Dahal A, Nahirya-Ntege P, Kekitiinwa A.

J Healthc Leadersh. 2018 Apr 23;10:21-32. doi: 10.2147/JHL.S147885. eCollection 2018.

17.

Whole-Exome Sequencing Reveals Uncaptured Variation and Distinct Ancestry in the Southern African Population of Botswana.

Retshabile G, Mlotshwa BC, Williams L, Mwesigwa S, Mboowa G, Huang Z, Rustagi N, Swaminathan S, Katagirya E, Kyobe S, Wayengera M, Kisitu GP, Kateete DP, Wampande EM, Maplanka K, Kasvosve I, Pettitt ED, Matshaba M, Nsangi B, Marape M, Tsimako-Johnstone M, Brown CW, Yu F, Kekitiinwa A, Joloba M, Mpoloka SW, Mardon G, Anabwani G, Hanchard NA; Collaborative African Genomics Network (CAfGEN) of the H3Africa Consortium.

Am J Hum Genet. 2018 May 3;102(5):731-743. doi: 10.1016/j.ajhg.2018.03.010. Epub 2018 Apr 26.

18.

Multicountry Validation of SAMBA - A Novel Molecular Point-of-Care Test for HIV-1 Detection in Resource-Limited Setting.

Ondiek J, Namukaya Z, Mtapuri-Zinyowera S, Balkan S, Elbireer A, Ushiro Lumb I, Kiyaga C, Goel N, Ritchie A, Ncube P, Omuomu K, Ndiege K, Kekitiinwa A, Mangwanya D, Fowler MG, Nadala L, Lee H.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):e52-e57. doi: 10.1097/QAI.0000000000001476.

PMID:
28902680
19.

Quality Improvement Interventions for Nutritional Assessment among Pregnant Mothers in Northeastern Uganda.

Izudi J, Epidu C, Katawera A, Kekitiinwa A.

Biomed Res Int. 2017;2017:8036535. doi: 10.1155/2017/8036535. Epub 2017 May 30.

20.

Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda.

Ssebunya R, Wanyenze RK, Lukolyo H, Mutto M, Kisitu G, Amuge P, Maganda A, Kekitiinwa A.

BMC Infect Dis. 2017 Jun 19;17(1):439. doi: 10.1186/s12879-017-2550-2.

21.

Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.

Kekitiinwa A, Szubert AJ, Spyer M, Katuramu R, Musiime V, Mhute T, Bakeera-Kitaka S, Senfuma O, Walker AS, Gibb DM; ARROW Trial Team.

Pediatr Infect Dis J. 2017 Jun;36(6):588-594. doi: 10.1097/INF.0000000000001505.

22.

The collaborative African genomics network training program: a trainee perspective on training the next generation of African scientists.

Mlotshwa BC, Mwesigwa S, Mboowa G, Williams L, Retshabile G, Kekitiinwa A, Wayengera M, Kyobe S, Brown CW, Hanchard NA, Mardon G, Joloba M, Anabwani G, Mpoloka SW.

Genet Med. 2017 Jul;19(7):826-833. doi: 10.1038/gim.2016.177. Epub 2017 Apr 6.

23.

Quality Improvement Interventions for Early HIV Infant Diagnosis in Northeastern Uganda.

Izudi J, Akot A, Kisitu GP, Amuge P, Kekitiinwa A.

Biomed Res Int. 2016;2016:5625364. doi: 10.1155/2016/5625364. Epub 2016 Dec 26.

24.

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.

AIDS. 2017 Apr 24;31(7):905-915. doi: 10.1097/QAD.0000000000001376.

25.

Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.

Abongomera G, Cook A, Musiime V, Chabala C, Lamorde M, Abach J, Thomason M, Mulenga V, Kekitiinwa A, Colebunders R, Kityo C, Walker AS, Gibb DM.

AIDS Behav. 2017 Feb;21(2):441-449. doi: 10.1007/s10461-016-1582-8.

26.

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.

Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P.

J Antimicrob Chemother. 2017 Jan;72(1):190-199. Epub 2016 Oct 5.

27.

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis.

Prendergast AJ, Bwakura-Dangarembizi M, Mugyenyi P, Lutaakome J, Kekitiinwa A, Thomason MJ, Gibb DM, Walker AS; ARROW Trial Team.

AIDS. 2016 Nov 28;30(18):2823-2829.

28.

Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.

Kekitiinwa A, Musiime V, Thomason MJ, Mirembe G, Lallemant M, Nakalanzi S, Baptiste D, Walker AS, Gibb DM, Judd A.

Antivir Ther. 2016;21(7):579-585. doi: 10.3851/IMP3054. Epub 2016 Apr 29.

29.

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):161-8. doi: 10.1097/QAI.0000000000001032.

30.

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.

Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team.

BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.

31.

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.

Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P.

Br J Clin Pharmacol. 2016 Jul;82(1):185-98. doi: 10.1111/bcp.12934. Epub 2016 Apr 25.

32.

Use of peers, community lay persons and Village Health Team (VHT) members improves six-week postnatal clinic (PNC) follow-up and Early Infant HIV Diagnosis (EID) in urban and rural health units in Uganda: A one-year implementation study.

Namukwaya Z, Barlow-Mosha L, Mudiope P, Kekitiinwa A, Matovu JN, Musingye E, Ssebaggala JN, Nakyanzi T, Abwooli JJ, Mirembe D, Etima J, Bitarakwate E, Fowler MG, Musoke PM; Peer-senga study Group at Mulago, Mengo, Rubaga and Mpigi Health Units.

BMC Health Serv Res. 2015 Dec 15;15:555. doi: 10.1186/s12913-015-1213-5.

33.

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team.

Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.

34.

Availability of Human Immunodeficiency Virus Prevention Services in Secondary Schools in Kabarole District, Uganda.

Namuddu J, Waiswa P, Nsangi B, Iriso R, Matovu J, Maganda A, Kekitiinwa A.

J Public Health Afr. 2015 Aug 17;6(2):454. doi: 10.4081/jphia.2015.454. eCollection 2015 Aug 17.

35.

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.

Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Nathoo K, Prendergast AJ, Walker AS; ARROW Trial Team.

AIDS. 2015 Mar 13;29(5):609-18. doi: 10.1097/QAD.0000000000000590.

36.

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team.

Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.

37.

Research capacity. Enabling the genomic revolution in Africa.

H3Africa Consortium, Rotimi C, Abayomi A, Abimiku A, Adabayeri VM, Adebamowo C, Adebiyi E, Ademola AD, Adeyemo A, Adu D, Affolabi D, Agongo G, Ajayi S, Akarolo-Anthony S, Akinyemi R, Akpalu A, Alberts M, Alonso Betancourt O, Alzohairy AM, Ameni G, Amodu O, Anabwani G, Andersen K, Arogundade F, Arulogun O, Asogun D, Bakare R, Balde N, Baniecki ML, Beiswanger C, Benkahla A, Bethke L, Boehnke M, Boima V, Brandful J, Brooks AI, Brosius FC, Brown C, Bucheton B, Burke DT, Burnett BG, Carrington-Lawrence S, Carstens N, Chisi J, Christoffels A, Cooper R, Cordell H, Crowther N, Croxton T, de Vries J, Derr L, Donkor P, Doumbia S, Duncanson A, Ekem I, El Sayed A, Engel ME, Enyaru JC, Everett D, Fadlelmola FM, Fakunle E, Fischbeck KH, Fischer A, Folarin O, Gamieldien J, Garry RF, Gaseitsiwe S, Gbadegesin R, Ghansah A, Giovanni M, Goesbeck P, Gomez-Olive FX, Grant DS, Grewal R, Guyer M, Hanchard NA, Happi CT, Hazelhurst S, Hennig BJ, Hertz- C, Fowler, Hide W, Hilderbrandt F, Hugo-Hamman C, Ibrahim ME, James R, Jaufeerally-Fakim Y, Jenkins C, Jentsch U, Jiang PP, Joloba M, Jongeneel V, Joubert F, Kader M, Kahn K, Kaleebu P, Kapiga SH, Kassim SK, Kasvosve I, Kayondo J, Keavney B, Kekitiinwa A, Khan SH, Kimmel P, King MC, Kleta R, Koffi M, Kopp J, Kretzler M, Kumuthini J, Kyobe S, Kyobutungi C, Lackland DT, Lacourciere KA, Landouré G, Lawlor R, Lehner T, Lesosky M, Levitt N, Littler K, Lombard Z, Loring JF, Lyantagaye S, Macleod A, Madden EB, Mahomva CR, Makani J, Mamven M, Marape M, Mardon G, Marshall P, Martin DP, Masiga D, Mason R, Mate-Kole M, Matovu E, Mayige M, Mayosi BM, Mbanya JC, McCurdy SA, McCarthy MI, McIlleron H, Mc'Ligeyo SO, Merle C, Mocumbi AO, Mondo C, Moran JV, Motala A, Moxey-Mims M, Mpoloka WS, Msefula CL, Mthiyane T, Mulder N, Mulugeta Gh, Mumba D, Musuku J, Nagdee M, Nash O, Ndiaye D, Nguyen AQ, Nicol M, Nkomazana O, Norris S, Nsangi B, Nyarko A, Nyirenda M, Obe E, Obiakor R, Oduro A, Ofori-Acquah SF, Ogah O, Ogendo S, Ohene-Frempong K, Ojo A, Olanrewaju T, Oli J, Osafo C, Ouwe Missi Oukem-Boyer O, Ovbiagele B, Owen A, Owolabi MO, Owolabi L, Owusu-Dabo E, Pare G, Parekh R, Patterton HG, Penno MB, Peterson J, Pieper R, Plange-Rhule J, Pollak M, Puzak J, Ramesar RS, Ramsay M, Rasooly R, Reddy S, Sabeti PC, Sagoe K, Salako T, Samassékou O, Sandhu MS, Sankoh O, Sarfo FS, Sarr M, Shaboodien G, Sidibe I, Simo G, Simuunza M, Smeeth L, Sobngwi E, Soodyall H, Sorgho H, Sow Bah O, Srinivasan S, Stein DJ, Susser ES, Swanepoel C, Tangwa G, Tareila A, Tastan Bishop O, Tayo B, Tiffin N, Tinto H, Tobin E, Tollman SM, Traoré M, Treadwell MJ, Troyer J, Tsimako-Johnstone M, Tukei V, Ulasi I, Ulenga N, van Rooyen B, Wachinou AP, Waddy SP, Wade A, Wayengera M, Whitworth J, Wideroff L, Winkler CA, Winnicki S, Wonkam A, Yewondwos M, sen T, Yozwiak N, Zar H.

Science. 2014 Jun 20;344(6190):1346-8. doi: 10.1126/science.1251546. No abstract available.

38.

The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.

Musiime V, Fillekes Q, Kekitiinwa A, Kendall L, Keishanyu R, Namuddu R, Young N, Opilo W, Lallemant M, Walker AS, Burger D, Gibb DM.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):148-54. doi: 10.1097/QAI.0000000000000135.

PMID:
24828266
39.

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.

Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, Kenny J, Wavamunno P, Komunyena J, Kabamba D, Asiimwe AR, Mirembe G, Abongomera G, Mulenga V, Kekitiinwa A, Kityo C, Walker SA, Klein N, Gibb DM; CHAPAS-3 trial team.

Antivir Ther. 2014;19(3):269-76. doi: 10.3851/IMP2695. Epub 2013 Oct 25.

PMID:
24717427
40.

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.

Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ.

N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.

41.

Do diagnosis delays impact receipt of test results? Evidence from the HIV early infant diagnosis program in Uganda.

Mugambi ML, Deo S, Kekitiinwa A, Kiyaga C, Singer ME.

PLoS One. 2013 Nov 1;8(11):e78891. doi: 10.1371/journal.pone.0078891. eCollection 2013.

42.

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.

Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, Nahirya Ntege P, Gibb DM, Thiebaut R, Walker AS, Klein N, Callard R; ARROW Trial Team.

PLoS Med. 2013 Oct;10(10):e1001542. doi: 10.1371/journal.pmed.1001542. Epub 2013 Oct 29.

43.

Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda.

Tukei VJ, Murungi M, Asiimwe AR, Migisha D, Maganda A, Bakeera-Kitaka S, Kalyesubula I, Musoke P, Kekitiinwa A.

BMC Pediatr. 2013 Mar 27;13:42. doi: 10.1186/1471-2431-13-42.

44.

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.

Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, Katabira E, Gilks CF, Kityo C, Nahirya-Ntege P, Nathoo K, Gibb DM; DART and ARROW trial teams.

Clin Infect Dis. 2012 Dec;55(12):1707-18. doi: 10.1093/cid/cis797. Epub 2012 Sep 12.

45.

Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.

Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR.

J Int AIDS Soc. 2012 Jul 2;15(2):17427. doi: 10.7448/IAS.15.2.17427.

46.

Prospective long-term outcomes of a cohort of Ugandan children with laboratory monitoring during antiretroviral therapy.

Kekitiinwa A, Asiimwe AR, Kasirye P, Korutaro V, Kitaka S, Maganda A, Madalon M, Graziano FM.

Pediatr Infect Dis J. 2012 Aug;31(8):e117-25. doi: 10.1097/INF.0b013e31825cb9d6.

PMID:
22581223
47.

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.

Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS; ARROW Trial Team.

Clin Pharmacol Ther. 2012 Feb;91(2):272-80. doi: 10.1038/clpt.2011.225. Epub 2011 Dec 21.

PMID:
22190066
48.

Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda.

Tukei VJ, Asiimwe A, Maganda A, Atugonza R, Sebuliba I, Bakeera-Kitaka S, Musoke P, Kalyesubula I, Kekitiinwa A.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):274-80. doi: 10.1097/QAI.0b013e3182423668.

PMID:
22126740
49.

Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy.

Bakeera-Kitaka S, Conesa-Botella A, Dhabangi A, Maganda A, Kekitiinwa A, Colebunders R, Boulware DR.

Int J Tuberc Lung Dis. 2011 Aug;15(8):1082-6. doi: 10.5588/ijtld.10.0538.

50.

Prevalence and outcome of HIV-associated malignancies among children.

Tukei VJ, Kekitiinwa A, Beasley RP.

AIDS. 2011 Sep 10;25(14):1789-93. doi: 10.1097/QAD.0b013e3283498115.

PMID:
21673560

Supplemental Content

Loading ...
Support Center